Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 6.

Article

Sartor, O., Coleman, R.E. orcid.org/0000-0002-4275-1043, Nilsson, S. et al. (11 more authors) (2017) An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Annals of Oncology. ISSN 0923-7534

Parker, C., Zhan, L., Cislo, P. et al. (6 more authors) (2017) Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. European Journal of Cancer, 71. C. pp. 1-6. ISSN 0959-8049

Parker, C., Finkelstein, S.E., Michalski, J.M. et al. (9 more authors) (2016) Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. European Urology, 70 (5). pp. 875-883. ISSN 0302-2838

Vogelzang, N.J., Coleman, R.E. orcid.org/0000-0002-4275-1043, Michalski, J.M. et al. (8 more authors) (2016) Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clinical Genitourinary Cancer. ISSN 1558-7673

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096

Nilsson, S., Cislo, P., Sartor, O. et al. (7 more authors) (2016) Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Annals of Oncology, 27 (5). pp. 868-874. ISSN 0923-7534

This list was generated on Sun Jul 21 00:30:25 2019 BST.